Cibus Q4 Net Loss Widens; Expects To Expand Rice Program Across The US, LATAM, And India In 2026

Cibus announced Q4 2025 financial results and issued commercial milestone targets tied to its plant-trait licensing business, but the article provided no revenue, EPS or numeric guidance. The company reiterated its focus on developing and licensing plant traits to seed companies, signaling progress toward commercialization milestones that could translate into future royalty or licensing revenue. Monitor the company’s filings and milestone disclosures for the specific metrics that would drive a meaningful stock move.

Analysis

Cibus announced Q4 2025 financial results and issued commercial milestone targets tied to its plant-trait licensing business, but the article provided no revenue, EPS or numeric guidance. The company reiterated its focus on developing and licensing plant traits to seed companies, signaling progress toward commercialization milestones that could translate into future royalty or licensing revenue. Monitor the company’s filings and milestone disclosures for the specific metrics that would drive a meaningful stock move.